Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 87063-305

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 87063-305). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (41d7651e B91a 4118 8719 Bf2f663d82a2 01)

Chemical structure of donepezil hydrochloride, depicted as a molecular diagram showing the arrangement of its aromatic rings, methoxy groups, piperidine ring, and hydrochloride component.*

FDA Label Image

Figure 1 (41d7651e B91a 4118 8719 Bf2f663d82a2 02)

A line graph showing ADAS-cog mean change from baseline (±SE) over weeks of drug treatment comparing donepezil hydrochloride 10 mg/day, donepezil hydrochloride 5 mg/day, and placebo groups. The graph indicates clinical improvement and decline with time on treatment and placebo phases.*

FDA Label Image

Figure 2 (41d7651e B91a 4118 8719 Bf2f663d82a2 03)

A line graph showing the cumulative percentage of patients over change from baseline in ADAS-cog scores for three treatment groups: Donepezil hydrochloride 10 mg/day, Donepezil hydrochloride 5 mg/day, and Placebo. The graph uses different markers to differentiate the groups and highlights points indicating clinical significance at 4 and 7 points of change.*

FDA Label Image

Figure 3 (41d7651e B91a 4118 8719 Bf2f663d82a2 04)

A bar chart displaying the percentage of patients by CIBIC-plus rating categories comparing donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo groups. Ratings range from markedly improved to markedly worse, showing differences in patient response levels across these treatments.*

FDA Label Image

Figure 4 (41d7651e B91a 4118 8719 Bf2f663d82a2 05)

A line graph showing ADAS-cog mean change from baseline with standard error bars over 15 weeks for donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The x-axis represents weeks of drug treatment, and the y-axis shows change from baseline, indicating clinical improvement or decline. The graph compares cognitive changes across the three groups over time.*

FDA Label Image

Figure 5 (41d7651e B91a 4118 8719 Bf2f663d82a2 06)

A line graph depicting the cumulative percentage of patients versus change from baseline for three treatment groups: Donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The graph shows patient response over a range of changes with labels indicating points of 7, 4, and no change. A small table summarizes the change in ADAS-cog scores and patient response percentages for each group.*

FDA Label Image

Figure 6 (41d7651e B91a 4118 8719 Bf2f663d82a2 07)

A bar chart displaying the CIBIC-plus rating distribution of patients comparing Aricept 10 mg/day, Aricept 5 mg/day, and placebo groups. The x-axis shows categories from 'Markedly Improved' to 'Markedly Worse,' and the y-axis represents the percentage of patients. The chart indicates various response levels across different treatment groups.*

FDA Label Image

Figure 7 (41d7651e B91a 4118 8719 Bf2f663d82a2 08)

A line graph depicting the change from baseline in SIB (Severe Impairment Battery) scores over six months of drug treatment. It compares two groups: one receiving donepezil hydrochloride 10 mg/day, showing clinical improvement, and a placebo group showing clinical decline. The x-axis represents months of treatment, and the y-axis shows the magnitude of change from baseline.*

FDA Label Image

Figure 8 (41d7651e B91a 4118 8719 Bf2f663d82a2 09)

A line graph comparing the cumulative percentage of patients over time with changes in SIB (Severe Impairment Battery) scores from baseline for Donepezil hydrochloride 10 mg/day versus placebo. The graph shows two lines representing the treatment and placebo groups, depicting changes in cognitive function scores over a period.*

FDA Label Image

Figure 9 (41d7651e B91a 4118 8719 Bf2f663d82a2 10)

A line graph showing the ADCS-ADL change from baseline (mean ± SE) over 0, 3, and 6 months of drug treatment comparing donepezil hydrochloride 10 mg/day to placebo. The y-axis represents change from baseline, with clinical improvement above and clinical decline below. The trend shows less decline for the donepezil group compared to placebo over time.*

FDA Label Image

Figure 10 (41d7651e B91a 4118 8719 Bf2f663d82a2 11)

A cumulative percentage of patients plot comparing donepezil hydrochloride 10 mg/day to placebo, showing ADCS-ADL change from baseline on the horizontal axis and cumulative percentage on the vertical axis. The graph illustrates patient response differences between treatment and placebo groups.*

FDA Label Image

10 (Label 10mg)

Labels for Donepezil hydrochloride Tablets USP 10 mg film-coated oral tablets packaged by Enovachem Pharmaceuticals and distributed by Solco Healthcare US, LLC. Labels show various package quantities including 20, 30, 60, 90, and 100 tablets with NDCs 87063-304-20, 87063-304-30, 87063-304-60, 87063-304-90, and 87063-304-01 respectively, including barcode and cautionary statements about prescription-only status and storage conditions.*

FDA Label Image

5 (Label 5mg)

Multiple packaging labels for Donepezil HCl Tablets USP 5 mg from Enovachem Pharmaceuticals. Labels detail various quantities including 20, 30, 60, and 100 tablets. Each label includes NDC codes, QR codes, distributor information (Solco Healthcare US, LLC), batch and expiration placeholders, and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.